RU2302880C2 - Новый специфический механизм ингибирования адгезии тромбоцитов к коллагену - Google Patents
Новый специфический механизм ингибирования адгезии тромбоцитов к коллагену Download PDFInfo
- Publication number
- RU2302880C2 RU2302880C2 RU2003107919/15A RU2003107919A RU2302880C2 RU 2302880 C2 RU2302880 C2 RU 2302880C2 RU 2003107919/15 A RU2003107919/15 A RU 2003107919/15A RU 2003107919 A RU2003107919 A RU 2003107919A RU 2302880 C2 RU2302880 C2 RU 2302880C2
- Authority
- RU
- Russia
- Prior art keywords
- saratin
- collagen
- platelet
- catheter
- endarterectomy
- Prior art date
Links
- 229920001436 collagen Polymers 0.000 title claims abstract description 83
- 102000008186 Collagen Human genes 0.000 title claims abstract description 79
- 108010035532 Collagen Proteins 0.000 title claims abstract description 79
- 230000005764 inhibitory process Effects 0.000 title description 16
- 230000007246 mechanism Effects 0.000 title description 5
- 108010011655 saratin Proteins 0.000 claims abstract description 147
- 238000013171 endarterectomy Methods 0.000 claims abstract description 41
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 34
- 210000001367 artery Anatomy 0.000 claims abstract description 30
- 239000000017 hydrogel Substances 0.000 claims abstract description 22
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 19
- 230000006378 damage Effects 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 208000037803 restenosis Diseases 0.000 claims abstract description 14
- 230000001419 dependent effect Effects 0.000 claims abstract description 11
- 241000237902 Hirudo medicinalis Species 0.000 claims abstract description 7
- 210000001715 carotid artery Anatomy 0.000 claims description 47
- 238000000576 coating method Methods 0.000 claims description 44
- 239000011248 coating agent Substances 0.000 claims description 29
- 229920000642 polymer Polymers 0.000 claims description 29
- 238000002399 angioplasty Methods 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 8
- 230000003966 vascular damage Effects 0.000 claims description 7
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- -1 poly (lactides) Polymers 0.000 claims description 5
- 230000009805 platelet accumulation Effects 0.000 claims description 4
- 230000002785 anti-thrombosis Effects 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 2
- 229920000249 biocompatible polymer Polymers 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229920002721 polycyanoacrylate Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 101710097567 12 kDa protein Proteins 0.000 claims 2
- 101710164418 Movement protein TGB2 Proteins 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 201000000054 Coronary Restenosis Diseases 0.000 claims 1
- 206010056489 Coronary artery restenosis Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 230000003872 anastomosis Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims 1
- 150000002905 orthoesters Chemical class 0.000 claims 1
- 229920006324 polyoxymethylene Polymers 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 20
- 208000032843 Hemorrhage Diseases 0.000 abstract description 19
- 208000034158 bleeding Diseases 0.000 abstract description 19
- 230000000740 bleeding effect Effects 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 17
- 238000001356 surgical procedure Methods 0.000 abstract description 16
- 230000009885 systemic effect Effects 0.000 abstract description 15
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 7
- 238000009825 accumulation Methods 0.000 abstract description 6
- 241000545744 Hirudinea Species 0.000 abstract description 4
- 230000003247 decreasing effect Effects 0.000 abstract description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 2
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 description 115
- 241000700159 Rattus Species 0.000 description 44
- 238000000034 method Methods 0.000 description 41
- 206010020718 hyperplasia Diseases 0.000 description 39
- 102100036537 von Willebrand factor Human genes 0.000 description 33
- 229960001134 von willebrand factor Drugs 0.000 description 32
- 108010047303 von Willebrand Factor Proteins 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 13
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 13
- 230000002776 aggregation Effects 0.000 description 12
- 238000004220 aggregation Methods 0.000 description 12
- 244000309466 calf Species 0.000 description 12
- 230000000699 topical effect Effects 0.000 description 11
- 208000031481 Pathologic Constriction Diseases 0.000 description 10
- 231100000673 dose–response relationship Toxicity 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000036262 stenosis Effects 0.000 description 10
- 208000037804 stenosis Diseases 0.000 description 10
- 239000000178 monomer Substances 0.000 description 9
- 102000012422 Collagen Type I Human genes 0.000 description 8
- 108010022452 Collagen Type I Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000013172 carotid endarterectomy Methods 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000010118 platelet activation Effects 0.000 description 7
- 230000002980 postoperative effect Effects 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003999 initiator Substances 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 102000001187 Collagen Type III Human genes 0.000 description 5
- 108010069502 Collagen Type III Proteins 0.000 description 5
- 101000621371 Homo sapiens WD and tetratricopeptide repeats protein 1 Proteins 0.000 description 5
- 101000892274 Human adenovirus C serotype 2 Adenovirus death protein Proteins 0.000 description 5
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
- 101000820656 Rattus norvegicus Seminal vesicle secretory protein 4 Proteins 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 230000003143 atherosclerotic effect Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001732 thrombotic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 3
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 3
- 108010081391 Ristocetin Proteins 0.000 description 3
- 229960004676 antithrombotic agent Drugs 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 229950004257 ristocetin Drugs 0.000 description 3
- 238000007631 vascular surgery Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- YCIGYTFKOXGYTA-UHFFFAOYSA-N 4-(3-cyanopropyldiazenyl)butanenitrile Chemical compound N#CCCCN=NCCCC#N YCIGYTFKOXGYTA-UHFFFAOYSA-N 0.000 description 2
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- 206010007688 Carotid artery thrombosis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000010102 embolization Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001453 nonthrombogenic effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 239000003505 polymerization initiator Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 229960005202 streptokinase Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 1
- GWZMWHWAWHPNHN-UHFFFAOYSA-N 2-hydroxypropyl prop-2-enoate Chemical compound CC(O)COC(=O)C=C GWZMWHWAWHPNHN-UHFFFAOYSA-N 0.000 description 1
- FQRHOOHLUYHMGG-BTJKTKAUSA-N 3-(2-acetylphenothiazin-10-yl)propyl-dimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FQRHOOHLUYHMGG-BTJKTKAUSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- 101710122462 65 kDa protein Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010048623 Collagen Receptors Proteins 0.000 description 1
- 102000009268 Collagen Receptors Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000237664 Haementeria officinalis Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- 206010050902 Postoperative thrombosis Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- OKKRPWIIYQTPQF-UHFFFAOYSA-N Trimethylolpropane trimethacrylate Chemical compound CC(=C)C(=O)OCC(CC)(COC(=O)C(C)=C)COC(=O)C(C)=C OKKRPWIIYQTPQF-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 229920006099 Vestamid® Polymers 0.000 description 1
- JUIBLDFFVYKUAC-UHFFFAOYSA-N [5-(2-ethylhexanoylperoxy)-2,5-dimethylhexan-2-yl] 2-ethylhexaneperoxoate Chemical compound CCCCC(CC)C(=O)OOC(C)(C)CCC(C)(C)OOC(=O)C(CC)CCCC JUIBLDFFVYKUAC-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229960001946 acepromazine maleate Drugs 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000012662 bulk polymerization Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- OIWOHHBRDFKZNC-UHFFFAOYSA-N cyclohexyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC1CCCCC1 OIWOHHBRDFKZNC-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000009556 duplex ultrasonography Methods 0.000 description 1
- 238000013156 embolectomy Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 108010078346 fibrin destabilase Proteins 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- BBKFSSMUWOMYPI-UHFFFAOYSA-N gold palladium Chemical compound [Pd].[Au] BBKFSSMUWOMYPI-UHFFFAOYSA-N 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QRWOVIRDHQJFDB-UHFFFAOYSA-N isobutyl cyanoacrylate Chemical class CC(C)COC(=O)C(=C)C#N QRWOVIRDHQJFDB-UHFFFAOYSA-N 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 108010076401 isopeptidase Proteins 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 108010081580 platelet adhesion inhibitor Proteins 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000000719 purinergic P2Y receptor antagonist Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 230000015590 smooth muscle cell migration Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005315 stained glass Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00118542 | 2000-08-25 | ||
| EP00118542.0 | 2000-08-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003107919A RU2003107919A (ru) | 2004-09-10 |
| RU2302880C2 true RU2302880C2 (ru) | 2007-07-20 |
Family
ID=8169664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003107919/15A RU2302880C2 (ru) | 2000-08-25 | 2001-08-23 | Новый специфический механизм ингибирования адгезии тромбоцитов к коллагену |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6881722B2 (OSRAM) |
| EP (1) | EP1311284B1 (OSRAM) |
| JP (1) | JP4988131B2 (OSRAM) |
| KR (1) | KR100794277B1 (OSRAM) |
| CN (1) | CN1224421C (OSRAM) |
| AR (1) | AR030492A1 (OSRAM) |
| AT (1) | ATE285246T1 (OSRAM) |
| AU (2) | AU9550601A (OSRAM) |
| BR (1) | BR0113478A (OSRAM) |
| CA (1) | CA2419385C (OSRAM) |
| CZ (1) | CZ302353B6 (OSRAM) |
| DE (1) | DE60107962T2 (OSRAM) |
| DK (1) | DK1311284T3 (OSRAM) |
| EC (1) | ECSP034485A (OSRAM) |
| ES (1) | ES2234896T3 (OSRAM) |
| HU (1) | HU229367B1 (OSRAM) |
| MX (1) | MXPA03001604A (OSRAM) |
| MY (1) | MY128992A (OSRAM) |
| NO (1) | NO331326B1 (OSRAM) |
| PT (1) | PT1311284E (OSRAM) |
| RU (1) | RU2302880C2 (OSRAM) |
| SI (1) | SI1311284T1 (OSRAM) |
| SK (1) | SK287829B6 (OSRAM) |
| UA (1) | UA77402C2 (OSRAM) |
| WO (1) | WO2002015919A2 (OSRAM) |
| ZA (1) | ZA200302296B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4805461B2 (ja) * | 1999-03-18 | 2011-11-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血小板接着の阻止用タンパク質 |
| MXPA05006043A (es) | 2003-01-10 | 2006-01-30 | Ablynx Nv | Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas. |
| US7691839B2 (en) | 2005-09-28 | 2010-04-06 | Biovascular, Inc. | Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation |
| US20110034396A1 (en) * | 2005-09-28 | 2011-02-10 | Biovascular, Inc. | Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions |
| US20080069774A1 (en) * | 2005-11-17 | 2008-03-20 | Lance Liotta | Proteomic antisense molecular shield and targeting |
| EP3846867B1 (en) * | 2018-09-06 | 2025-02-19 | Biomodics APS | A medical tubular device |
| CN117229423B (zh) * | 2023-11-10 | 2024-02-06 | 北京科技大学 | 一种用于结合胶原的多肽纳米材料及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879135A (en) * | 1984-07-23 | 1989-11-07 | University Of Medicine And Dentistry Of New Jersey | Drug bonded prosthesis and process for producing same |
| WO1992007005A1 (en) * | 1990-10-10 | 1992-04-30 | Merck Patent Gmbh | Platelet adhesion inhibitor |
| WO1998008552A1 (en) * | 1995-08-22 | 1998-03-05 | Medtronic, Inc. | Method for making improved heparinized biomaterials |
| RU2128705C1 (ru) * | 1991-09-05 | 1999-04-10 | Шеринг Аг | Протеин, ингибирующий вызываемую коллагеном агрегацию тромбоцитов млекопитающих, рекомбинантный протеин, ингибирующий вызываемую коллагеном агрегацию тромбоцитов, фрагмент днк, кодирующий рекомбинантный протеин, вектор экспрессии (варианты), штамм культивируемых животных клеток внк - продуцент рекомбинантного протеина (варианты), способ получения рекомбинантного протеина, фармацевтическая композиция |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947401A (en) * | 1971-10-05 | 1976-03-30 | Union Optics Corporation | Hydrogels of unsaturated ester copolymers |
| US5705355A (en) | 1984-03-27 | 1998-01-06 | Transgene, S.A. | Hirudin, pharmaceutical compositions comprising it and their use |
| US4898734A (en) * | 1988-02-29 | 1990-02-06 | Massachusetts Institute Of Technology | Polymer composite for controlled release or membrane formation |
| IL86857A (en) * | 1988-06-24 | 1994-04-12 | Yissum Res Dev Co | Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same |
| US5304121A (en) * | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| CA2052486A1 (en) * | 1990-10-09 | 1992-04-10 | Thomas M. Connolly | Protein for inhibiting collagen-stimulated platelet aggregation |
| US5179082A (en) * | 1990-11-13 | 1993-01-12 | Merck & Co., Inc. | Method for blocking platelet adhesion to collagen |
| DE4136513A1 (de) | 1991-11-06 | 1993-05-13 | Basf Ag | Neues thrombininhibitorisches protein aus raubwanzen |
| JP3742429B2 (ja) | 1993-07-01 | 2006-02-01 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | コラーゲン刺激血小板凝集の阻害剤 |
| ES2255477T5 (es) * | 1993-07-29 | 2010-04-08 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Uso de paclitaxel y sus derivados en la fabricacion de un medicamento para el tratamiento de reestenosis. |
| US5532287A (en) * | 1994-05-04 | 1996-07-02 | Ciba-Geigy Corporation | Radiation cured drug release controlling membrane |
| US6246715B1 (en) * | 1998-06-26 | 2001-06-12 | Samsung Electronics Co., Ltd. | Data transmitter and receiver of a DS-CDMA communication system |
| US5843172A (en) * | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
| WO2000023094A2 (en) * | 1998-10-16 | 2000-04-27 | Immunex Corporation | Methods of inhibiting platelet activation and recruitment |
| IT1304135B1 (it) * | 1998-11-26 | 2001-03-07 | Magneti Marelli Spa | Metodo di controllo dell' iniezione e dell' accensione in un motoreendotermico ad iniezione diretta per accelerare il riscaldamento del |
| JP2002537270A (ja) * | 1999-02-19 | 2002-11-05 | ザイモジェネティクス，インコーポレイティド | 止血及び免疫機能における使用のためのインヒビター |
| JP4805461B2 (ja) | 1999-03-18 | 2011-11-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血小板接着の阻止用タンパク質 |
-
2001
- 2001-08-22 MY MYPI20013935A patent/MY128992A/en unknown
- 2001-08-23 AT AT01976139T patent/ATE285246T1/de active
- 2001-08-23 HU HU0303747A patent/HU229367B1/hu not_active IP Right Cessation
- 2001-08-23 CN CNB018146600A patent/CN1224421C/zh not_active Expired - Fee Related
- 2001-08-23 KR KR1020037002188A patent/KR100794277B1/ko not_active Expired - Fee Related
- 2001-08-23 CZ CZ20030720A patent/CZ302353B6/cs not_active IP Right Cessation
- 2001-08-23 WO PCT/EP2001/009746 patent/WO2002015919A2/en not_active Ceased
- 2001-08-23 ES ES01976139T patent/ES2234896T3/es not_active Expired - Lifetime
- 2001-08-23 BR BR0113478-7A patent/BR0113478A/pt not_active Application Discontinuation
- 2001-08-23 UA UA2003032476A patent/UA77402C2/uk unknown
- 2001-08-23 SI SI200130310T patent/SI1311284T1/xx unknown
- 2001-08-23 EP EP01976139A patent/EP1311284B1/en not_active Expired - Lifetime
- 2001-08-23 CA CA2419385A patent/CA2419385C/en not_active Expired - Fee Related
- 2001-08-23 DK DK01976139T patent/DK1311284T3/da active
- 2001-08-23 AU AU9550601A patent/AU9550601A/xx active Pending
- 2001-08-23 JP JP2002520840A patent/JP4988131B2/ja not_active Expired - Fee Related
- 2001-08-23 PT PT01976139T patent/PT1311284E/pt unknown
- 2001-08-23 MX MXPA03001604A patent/MXPA03001604A/es active IP Right Grant
- 2001-08-23 RU RU2003107919/15A patent/RU2302880C2/ru not_active IP Right Cessation
- 2001-08-23 US US10/362,476 patent/US6881722B2/en not_active Expired - Fee Related
- 2001-08-23 SK SK313-2003A patent/SK287829B6/sk not_active IP Right Cessation
- 2001-08-23 DE DE60107962T patent/DE60107962T2/de not_active Expired - Lifetime
- 2001-08-23 AU AU2001295506A patent/AU2001295506B2/en not_active Ceased
- 2001-08-27 AR ARP010104073A patent/AR030492A1/es not_active Application Discontinuation
-
2003
- 2003-02-21 EC EC2003004485A patent/ECSP034485A/es unknown
- 2003-02-24 NO NO20030841A patent/NO331326B1/no not_active IP Right Cessation
- 2003-03-24 ZA ZA200302296A patent/ZA200302296B/en unknown
-
2004
- 2004-12-21 US US11/016,854 patent/US7459438B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879135A (en) * | 1984-07-23 | 1989-11-07 | University Of Medicine And Dentistry Of New Jersey | Drug bonded prosthesis and process for producing same |
| WO1992007005A1 (en) * | 1990-10-10 | 1992-04-30 | Merck Patent Gmbh | Platelet adhesion inhibitor |
| RU2128705C1 (ru) * | 1991-09-05 | 1999-04-10 | Шеринг Аг | Протеин, ингибирующий вызываемую коллагеном агрегацию тромбоцитов млекопитающих, рекомбинантный протеин, ингибирующий вызываемую коллагеном агрегацию тромбоцитов, фрагмент днк, кодирующий рекомбинантный протеин, вектор экспрессии (варианты), штамм культивируемых животных клеток внк - продуцент рекомбинантного протеина (варианты), способ получения рекомбинантного протеина, фармацевтическая композиция |
| WO1998008552A1 (en) * | 1995-08-22 | 1998-03-05 | Medtronic, Inc. | Method for making improved heparinized biomaterials |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3618736B2 (ja) | トロンビン由来ペプチドを使用した治療法 | |
| US20110244014A1 (en) | Implantable medical articles having laminin coatings and methods of use | |
| JP2007532197A (ja) | 生物活性物質のための被覆組成物 | |
| US20120277852A1 (en) | Coating compositions, methods and coated devices | |
| JP2006297130A (ja) | 補足された及び補足されていない組織シーラント、その製造法及び使用法 | |
| Liu et al. | Surface modification with ECM-inspired SDF-1α/laminin-loaded nanocoating for vascular wound healing | |
| RU2302880C2 (ru) | Новый специфический механизм ингибирования адгезии тромбоцитов к коллагену | |
| Wang et al. | Chondroitin sulfate and Cys-Ala-Gly peptides coated ZE21B magnesium alloy for enhanced corrosion resistance and vascular compatibility | |
| AU2001295506A1 (en) | Saratin for inhibiting platelet adhesion to collagen | |
| Lin et al. | Carotid stenting using heparin-coated balloon-expandable stent reduces intimal hyperplasia in a baboon model | |
| RU2835436C1 (ru) | Способ изготовления функционально активной полимерной заплаты для артериальной реконструкции, устойчивой к аневризмообразованию | |
| HK1059736B (en) | A new specific mechanism for inhibiting platelet adhesion to collagen | |
| PL203469B1 (pl) | Zastosowanie polipeptydowej Saratyny do wytwarzania leku | |
| Anderson et al. | Technologies for the surface modification of biomaterials | |
| JP2002501789A (ja) | 医療用インプラントのための生体適合性を増強したコーティング | |
| JP2008535563A (ja) | 生物活性剤のためのコーティング組成物 | |
| Joshi | Designer Collagen-Fibril Biograft Materials for Tunable Molecular Delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150824 |